See You in Chicago 2019`
The 2019 National Patient Education Conference will be July 19-21 in Chicago! Will you join us?

Click here to learn more >>

Stepping Out to Cure Scleroderma
Take a Step for Scleroderma

Find a "Stepping Out to Cure Scleroderma" walk/run near you today!

Click here to get started >>

Learn about how scleroderma affects the body
Corbus RESOLVE-1 Study Web Ad
Learn about the RESOLVE-1 study and participating centers on clinicaltrials.gov

If you have questions,
contact Lindsey Smith

Who We Are

The Scleroderma Foundation is a federally qualified 501(c)(3) nonprofit dedicated to serving the needs of the scleroderma community.  Our primary goal is to raise funds and awareness for our three-fold mission of support, education and research.  All donations are qualified charitable donations to the fullest extent of the law.  Our federal tax identification number is 52-1375827.  All donations are gratefully accepted. 

What is Scleroderma?

Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. The word “scleroderma” comes from two Greek words: “sclero” meaning hard, and “derma” meaning skin. Hardening of the skin is one of the most visible manifestations of the disease.

Read more >>

Download Our Free Scleroderma Information Packet

Can’t download It? Have us mail you a copy!

GuideStar Gold StarSee our 2018 GuideStar Gold Star profile


Buzzworthy Reads>>

scleroderma body thumbnail vertical.jpg

News

Visit the eLetter Archive to read the stories behind these headlines.  Submit your email address to receive the eLetter every week.

eLetter #806; March 22, 2019

  • Register Today for the National Patient Education Conference, July 19-20-21, Chicago, Illinois
  • Taking Charge of Systemic Sclerosis
  • Results of Controlled Trial Evaluating Internet-Based Self-Management in Systemic Sclerosis
  • Stepping Out to Cure Scleroderma 2019, Plan Ahead for April Walks
  • Achieving Financial Independence with Ticket to Work and an ABLE Account, Webinar: Wednesday, March 27, 3 - 4:30 p.m. E.T.
  • FDA Public Meeting - Patient Perspectives on the Impact of Rare Diseases: Bridging the Commonalities, Monday, April 29, 1 - 5 p.m. E.T.
  • Can You Relate? myPHteam
  • Juvenile Scleroderma
  • Reach for the Cure
  • Clincal Trial Update/Opportunity
    • Safety and Tolerability Study of AVID200, a Novel TGF-beta 1 & 3 Inhibitor, in Patients with Diffuse Cutaneous Systemic Sclerosis
    • Localized Scleroderma Clinical Research Trial

 

 

E-Newsletter Signup

Get the latest news.

Please leave this field empty

Our Sponsors